Clinical and epidemiological features of the disease caused by the Ebola virus, at the present stage: pathogenetic basis of therapy


Cite item

Full Text

Abstract

Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever is severe acute infectious diseases accompanied by the development of severe systemic inflammatory response followed by the addition of disseminated intravascular coagulation and multiple organ failure. Since 1976 in Africa regularly observed disease outbreaks among humans caused by different types of Ebola virus. Modern epidemic in West Africa began in Guinea in February 2014 and is still going on, coming out of the country and distributed in Liberia, Sierra Leone and Nigeria. According to the World Health Organization (WHO) on December 14, 2014 recorded 18,603 cases of them confirmed EVD 11807, fatal 6915. From July 2014 to currently registered sporadic cases EVD among health care workers caring for patients, as well as among tourists returning from countries affected by the epidemic is already outside of West Africa. Due to the limited use of specific antiviral therapy with special attention to the management ofpatients with EVD should be paid to the intensive and timely pathogenetic therapy. Today, the only way to reduce morbidity and mortality among people from EVD is awareness on the risk factors of infection and the use ofpersonal protective measures.

About the authors

O. I Kiselev

Research Institute of Influenza

Email: office@influenza.spb.ru
акад. РАН, проф., директор ФГБУ «НИИ гриппа» Минздрава России 15/17, Professira Popova Str., Saint-Petersburg, Russian Federation, 197376

L. M Tsybalova

Research Institute of Influenza

Email: sovet@influenza.spb.ru
доктор мед. наук, зам. директора по научной работе 15/17, Professira Popova Str., Saint-Petersburg, Russian Federation, 197376

E. G Deeva

Research Institute of Influenza

Email: klinika@influenza.spb.ru
канд. мед. наук, гл. врач специализированной клиники вирусных инфекций 15/17, Professira Popova Str., Saint-Petersburg, Russian Federation, 197376

V. V Tsvetkov

Research Institute of Influenza

Email: suppcolor@gmail.com
аспирант, науч. сотр. 15/17, Professira Popova Str., Saint-Petersburg, Russian Federation, 197376

G. S Golobokov

Research Institute of Influenza

Email: llama228@yandex.ru
науч. сотр. 15/17, Professira Popova Str., Saint-Petersburg, Russian Federation, 197376

I. I Tokin

Research Institute of Influenza

Email: ivan.i.tokin@rambler.ru
канд. мед. наук, зав. отд-нием экспериментальной терапии вирусных гепатитов 15/17, Professira Popova Str., Saint-Petersburg, Russian Federation, 197376

T. V Sologub

Research Institute of Influenza

Email: sologub@influenza.spb.ru
доктор мед. наук, проф. зам. директора по научной и клинической работе 15/17, Professira Popova Str., Saint-Petersburg, Russian Federation, 197376

References

  1. Emergence of Zaire Ebola Virus Disease in Guinea: Preliminary Report April 16, 2014.
  2. CDC: http://www.cdc.gov/vhf/ebola/outbreaks/guinea/recent_updates.html
  3. Baron R.C., McCormick J.B., Zubeir O.A. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull. World Hlth Org. 1983; 61 (6): 997-1003.
  4. Sanchez A., Lukwiya M., Bausch D., Mahanty S., Sanchez A.J., Wagoner K.D., Rollin P.E. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol. 2004; 78 (19): 10370-7.
  5. Formenty P., Hatz C., Le Guenno B., Stoll A., Rogenmoser P., Widmer A. Human infection due to Ebola virus, subtype C@ote d’Ivoire: clinical and biologic presentation. J. Infect. Dis. 1999; 179 (Suppl 1): S48-53.
  6. Groseth A., Feldmann H., Strong J.E. The ecology of Ebola virus. Trends Microbiol. 2007; 15: 408-16.
  7. Mirkovic K., Thwing J., Diack P. A. Importation and containment of Ebola virus disease - Senegal, August-September 2014. Morbid. Mortal. Wkly Rep. 2014; 63 (39): 873-4.
  8. Dowell S.F., Mukunu R., Ksiazek T.G., Khan A.S., Rollin P.E., Peters C.J. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members. Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epid@emies @a Kikwit. J. Infect. Dis. 1999; 179 (Suppl 1): S87-91.
  9. CDC: Ebola virus sisease in West Africa. The first 9 months of the epidemic and forward projections. N. Engl. J. Med. 2014;
  10. Wei Xu, Gaya K. Amarasinghe et al. Ebola virus VP24 targets a unique NLS binding site on Karyopherin Alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe. 2014; 16 (2): 187-200.
  11. Knipe D. M., Peter M. Fields Virology. Howley. 6th Ed. 2014.
  12. World Health Organization. Ebola virus disease: Cuban medical team heading for Sierra Leone (http://www.who.int/csr/disease/ebola/en/).
  13. Reid S.P., Valmas C., Martinez O., Sanchez F.M., Basler C.F. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 2007; 81: 13469-77.
  14. Geisbert T.W., Hensley L.E., Larsen T. et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 2003; 163: 2347-70.
  15. Qiu X., Audet J., Wong G., Fernando L., Bello A., Pillet S. et al. (November 2013). Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep. 2013; 3: 3365.
  16. Geisbert T.W., Lee A.C., Robbins M., Geisbert J.B., Honko A.N., Sood V. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375 (9729): 1896-905.
  17. Wendy K., Chris E., Richard G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001; 357: 593-615.
  18. Furuta Y., Takahashi K., Shiraki K., Sakamoto K., Smee D.F., Barnard D.L. et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009; 82 (3): 95-102.
  19. Furuta Y., Gowen B. B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013; 100 (2): 446.
  20. Warren T.K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014; 508: 402-5.
  21. Hensley L.E. et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 2007; 196 (Suppl. 2): S390-9.
  22. Geisbert T.W. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesusmonkeys. Lancet. 2003; 362: 1953-8.
  23. Беланов Е.Ф., Разумов И.А., Чепурнов А.А., Перебоев А.В., Казачинская Е.И. Моноклональные антитела к вирусу Эбола: получение, характеристика и изучение перекрестной реактивности с вирусом Марбург. Вопросы вирусологии. 2000; 45 (3): 40-4.
  24. Чепурнов А.А., Тикунова Н.В., Батанова Т.А. Рекомбинантные антитела человека к вирусу Эбола: получение и характеристика. Вопросы вирусологии. 2005; 50 (5): 25-9.
  25. Кизимов Н.В., Кудоярова Н.М., Калиберов С.А. и др. Разработка лечебно-профилактических препаратов гамма-глобулина против болезней Марбург, Эбола, Боливийской геморрагической лихорадки. В кн.: Актуальные вопросы медицинской биотехнологии: Материалы научной конференции, посвященной 85-летию Томского НИИ вакцин и сывороток НПО «Вирион». Томск, 1991; 2: 31-2.
  26. Градобоев В.Н. Получение гипериммунной лошадиной сыворотки против вируса Эбола. Вопросы вирусологии. 1995; 40 (3): 138-40.
  27. Сергеев Н.Н. Разработка методов получения специфических гетерологичных иммуноглобулинов для экстренной профилактики лихорадки Эбола и изучение их свойств. Вестник РАМН. 1998; 4: 24-9.
  28. Warren T.K. et al. Advanced morpholino oligomers: a novel approach to antiviral therapy. Antiviral Res. 2008; 94: 80-8.
  29. Warren T.K. et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 2010; 16: 991-4.
  30. Kreuels B., Wichmann D., Emmerich P, Schmidt-Chanasit J., de Heer G., Kluge S. et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N. Engl. J. Med. 2014; Oct: 1-8.
  31. Киселев О.И., Платонов В.Г., Ильенко В.И., Деева Э.Г. Отчет по изучению противовирусной активности соединений ряда азоло-азинов, в том числе Триазавирина. Институт гриппа РАМН. 2000.
  32. Perner A., Haasw N., Guttormsen A.B., Tenhunen J., Klemenzon G. , Fneman A. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N. Engl. J. Med. 2012l 367 (2): 124-34.

Copyright (c) 2015 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies